This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > BIIB092 for progressive supranuclear palsy

< Back

BIIB092 for progressive supranuclear palsy


Neurology and Neurosurgery

February 2019

BIIB092 is a product that is being investigated for the treatment of progressive supranuclear palsy (PSP). PSP is a rare condition that is a result of destruction of nerve cells in certain parts of the brain causing problems with balance, movement, vision, speech and swallowing. In patients with PSP, an abnormal form of a protein called tau accumulates in specific areas of the brain by spreading from brain cell to brain cell leading to their damage. Over time, PSP gets progressively worse, with people becoming severely disabled within three to five years of onset. Currently, there is no cure for PSP and no treatment to slow down the disease.
BIIB092 is a monoclonal antibody that acts by recognising, binding to and neutralising a specific type of tau protein responsible for the nerve cells damage and gradual worsening of PSP. This action of BIIB092 is thought to prevent the spread of the disorder and potentially slow the progression of PSP. Tau-directed immunotherapy like BIIB092 offers a promising disease-modifying treatment strategy for PSP and similar conditions. BIIB092 is given by intravenous infusion and if licensed, will offer a more targeted treatment option for patients with PSP.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts